SUNSHINE BIOPHARMA'S LEAD ANTI-CANCER COMPOUND, Adva-27a, PERFORMS EXCEPTIONALLY WELL IN HUMAN MICROSOME STABILITY ASSAYS

MONTREAL, June 27, 2011 /PRNewswire/ - Sunshine Biopharma Inc. (OTCBB Ticker Symbol: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a human microsome stability study of its lead compound, Adva-27a targeted for aggressive types of cancer including multidrug resistant breast cancer.  The microsome stability test measures how quickly the drug is eliminated by the body.  Our results show that Adva-27a has intermediate clearance time (half-life = 54 minutes) similar to that of etoposide (half-life = 48 minutes) and other drugs currently on the market.

"This is perfect, Adva-27a meets the criteria of a good pharmaceutical drug", said Dr. Steve N. Slilaty, Sunshine's President and CEO.  "Rapid clearance (i.e. short half-life) is undesirable as the drug would not have enough time to act and slow clearance (i.e. long half-life) could result in the drug being too toxic to administer", he added.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

SOURCE Sunshine Biopharma Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED